Treatment Sequencing in Advanced RCC: Updates from 2023 ASCO GU

Video

Bradley McGregor, MD, discusses the current landscape for advanced renal cell carcinoma therapies, emerging clinical evidence, and considerations for optimal treatment sequencing.

Recent Videos
Solly Chedid, MD, and Jamie Koprivnikar, MD
Solly Chedid, MD, and Jamie Koprivnikar, MD
Rebecca A. Shatsky, MD, an expert on breast cancer
Rebecca A. Shatsky, MD, an expert on breast cancer
Rebecca A. Shatsky, MD, an expert on breast cancer
Rebecca A. Shatsky, MD, an expert on breast cancer
Rebecca A. Shatsky, MD, an expert on breast cancer
2 KOLs are featured in this program.
Related Content
Adding Nivolumab to Tivozanib Fails to Improve Outcomes in Metastatic Renal Cell Carcinoma

Adding Nivolumab to Tivozanib Fails to Improve Outcomes in Metastatic Renal Cell Carcinoma

Megan Hollasch
September 13th 2024
Article

When added to tivozanib, nivolumab did not lead to improved clinical outcomes in metastatic renal cell carcinoma.

Read More

Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC

Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC

Jordyn Sava;Peter Zang, MD
March 1st 2024
Podcast

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

Listen

Lenvatinib and Pembrolizumab Combo Breaks New Ground in Non–Clear Cell RCC

Lenvatinib and Pembrolizumab Combo Breaks New Ground in Non–Clear Cell RCC

Morgan Bayer
September 6th 2024
Article

There are remaining gaps in papillary renal cell carcinoma that data from 3 pending trials hope to fill.

Read More

Beyond the First-Line: Economides on Advancing Therapies in RCC

Beyond the First-Line: Economides on Advancing Therapies in RCC

Jordyn Sava;Minas P. Economides, MD
February 1st 2024
Podcast

In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.

Listen

Positive Responses Are Reported for Fianlimab/Cemiplimab in ccRCC

Positive Responses Are Reported for Fianlimab/Cemiplimab in ccRCC

Chris Ryan
September 4th 2024
Article

Fianlimab plus cemiplimab was well-tolerated and showed durable responses, in pretreated patients with advanced clear cell renal carcinoma.

Read More

Lenvatinib and Pembrolizumab Outperform Sunitinib in Advanced RCC

Lenvatinib and Pembrolizumab Outperform Sunitinib in Advanced RCC

Jordyn Sava
September 3rd 2024
Article

In an interview, Jaime Merchan, MD, explained the background and data from a biomarker analysis of the CLEAR trial in advanced renal cell carcinoma.

Read More